Clinical Trial Update: Sorafenib Tosylate in Treating Patients With Metastatic, Locally Advanced, or Recurrent Medullary Thyroid Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating sorafenib tosylate for metastatic, locally advanced, or recurrent medullary thyroid cancer; study completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Medullary Thyroid Carcinoma

Drugs mentioned

• Sorafenib tosylate (sorafenib tosylate)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Hereditary Thyroid Gland Medullary Carcinoma, Locally Advanced Thyroid Gland Medullary Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2018-12-21